Biophytis SA

Biophytis SA, based in France, specializes in developing innovative therapeutics for age-related diseases, focusing on enhancing patient functional outcomes through advanced medical treatments. Biophytis SA is dedicated to the development of therapeutics that combat age-related degenerative processes. Founded in 2006 in Paris, France, the company has engaged in multiple funding rounds, with a focus on private placements. The CEO, Stanislas Veillet, has previously been involved in other ventures.

The most recent substantial funding occurred in July 2015 with a PIPE round, raising EUR 600. 000. The company has completed a total of 8 deals, with the last recorded deal date being July 7, 2015. Biophytis develops innovative therapeutics targeting degenerative conditions related to aging.

Their key products include BIO101, aimed at treating neuromuscular diseases, and Macuneos, which focuses on retinal diseases. These therapeutics are designed to activate biological resilience pathways to mitigate the effects of age-related health issues, catering to markets in Europe and North America. In 2017, Biophytis reported zero revenue, with an EBITDA of EUR -13,085,828. 1.

The company primarily generates revenue through capital increases from private placements and partnerships, having completed a private placement of EUR 2. 6 million to support ongoing research and clinical programs. Their business model includes direct-to-consumer and B2B transactions, mainly within the pharmaceutical sector. Biophytis plans to launch new products designed to address various age-related conditions, although specific release dates remain unspecified.

The company is also targeting expansion into new geographic regions, particularly enhancing its presence in Europe and North America. The funding raised, particularly the EUR 10 million from the IPO in July 2015, will support these initiatives, contributing to research and enabling clinical trials for their flagship therapeutics.